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Abstract: Background: Von Hippel-Lindau (VHL) is an uncommon oncogenic disorder which occurs as a result of 
genetic mutations on chromosome 3p. Retinal capillary haemangiomas and CNS haemangioblastomas have been well-
characterised in genotypic-phenotypic analyses, but cystic visceral lesions are less common and have been less frequently 
studied. The aim of this study was to perform genotypic and phenotypic analysis of a cohort of VHL patients that 
developed cystic visceral lesions to determine whether their genotype differs from that seen in other manifestations of 
VHL and whether the ocular manifestations differ. 
Methods: This study reports a prospective case series of twenty-one patients identified from the Hammersmith Hospital 
Genetics Service database as having VHL mutations. Patients underwent regular ocular and systemic screening as well as 
genotypic analysis. The main outcome measures were the development of VHL lesions, either ocular or systemic. 
Results: Cystic visceral lesions were detected in six of the 21 patients from the clinic (29%). These included renal cysts in 
four patients, pancreatic cysts in three patients, and an epididymal cystadenoma in one patient. Renal cysts were not 
associated with any specific genotype. Pancreatic cysts appeared to occur in association with VHL gene deletions and all 
developed CNS haemangioblastomas. Only one patient developed ocular manifestations, which occurred in this patient in 
the form of two retinal capillary haemangiomas. 
Conclusions: VHL gene deletions appeared to be associated with pancreatic cysts and the development of CNS 
haemangioblastomas. Ocular manifestations are uncommon in this group of patients. 
Keywords: von Hippel-Lindau, retinal capillary haemangioma, epididymal cyst, renal cyst, gene deletion. 
INTRODUCTION 
 Von Hippel-Lindau disease (VHL) is a rare, multisystem, 
oncogenic disorder. Morphologically, it is characterised by 
multiple lesions of varying histological types [1-4], including 
benign cysts, benign vascular tumours and malignant 
tumours. There are six organ systems which are mainly 
affected, the CNS (Central Nervous System), retina, 
pancreas, kidney, adrenal gland and epididymis, and there 
are varying manifestations in each [1, 5]. Variable intra- and 
inter-familial expressivity is typical of VHL disease [6], but 
correlations have been demonstrated between mutational 
genotype and phenotype. For instance, deletions are 
associated with a low risk of pheochromocytoma, in contrast 
to missense mutations [1, 7-9]; a higher frequency of renal 
involvement has also been reported in truncating mutations 
compared to missense mutations [10]. Similarly, the risk of  
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retinal capillary haemangioma (RCH) is also affected by the 
genotype, occurring in 38% of patients with missense 
mutations and 40% of those with truncating mutations, but 
only 14% of those with deletions [11]. It has also been 
reported that truncating mutations lead to an earlier age of 
onset of RCH compared to missense mutations and deletions 
[12]. 
 However, the ocular manifestations of VHL which occur 
in patients with visceral cysts are much less well 
characterised and have not previously been reported. The 
aim of this study was to determine the ocular phenotype of 
patients identified as having visceral cysts and to assess any 
relationship with the underlying genotype. 
METHODS 
 In this study, we report a prospective case series of 
proven VHL disease gene carriers under the care of the VHL 
clinic at the Hammersmith Hospital, London, UK. Patients 
were eligible for inclusion in this study if they were 
undergoing follow-up in the VHL clinic and had proven 
VHL mutations on genotyping. Eligible participants were 
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invited for ophthalmic screening in addition to their routine 
systemic screening. At the initial clinic visit, a retrospective 
review of the case notes was undertaken. Data relating to 
ocular and systemic disease manifestations were then 
collected prospectively for two years. The type of VHL 
mutation was documented in each case, VHL mutations 
being categorised as missense mutations, truncating 
mutations, or deletions. 
 VHL disease features were noted and categorised into 
one of four groups: cystic visceral lesions, other visceral 
lesions, CNS manifestations and ocular features. All patients 
had a good fundal view and a complete ophthalmic 
examination was carried out at the first and all subsequent 
clinic visits, including indirect peripheral retinal 
examination. All fundal lesions were documented by colour 
fundus photography and fundus fluorescein angiography was 
performed when the diagnosis of a retinal capillary 
haemangioma was uncertain. 
RESULTS 
 Twenty-one patients were identified from the VHL clinic 
as carrying VHL disease genes and were thus eligible for 
inclusion in the study. All twenty-one agreed to participate in 
the study and to attend for ophthalmological screening. Of 
the 21 patients, eleven (52%) were male and ten (48%) were 
female. Twelve patients (57%) were Asian and nine (43%) 
were Caucasian; there were no patients of African or Afro-
Caribbean descent. The mean age at the time of VHL 
diagnosis was 25 years (range, 6 to 59 years), but patients 
with RCH were diagnosed at a younger age (mean 17 years 
vs 29 years for patients without RCH). 
 Six of the twenty-one patients (29%) either presented 
with visceral cysts or developed them during the follow-up 
period of two years. Disease manifestations and associated 
mutational genotypes are summarised in Table 1. One 
patient presented with an epididymal cystadenoma and one 
presented with a renal cyst. Three patients developed 
pancreatic cysts during follow-up and three patients 
developed renal cysts. All of these patients who developed 
pancreatic cysts had VHL gene deletions and all developed 
CNS HGB at some stage. Only one of the six patients 
developed ocular manifestations of VHL, namely retinal 
capillary haemangiomas; none of the other patients 
developed any ocular manifestations. 
DISCUSSION 
 We performed a study of patients with an atypical 
manifestation of VHL, namely visceral cysts, followed in a 
Genetics Clinic. Owing to their relatively benign nature, 
cystic visceral lesions have received comparatively less 
attention in relation to both their correlation with other 
phenotypic manifestations of VHL disease and genotypic 
associations. Cystic visceral lesions were detected in six of 
the 21 patients in the clinic (29%). These included renal 
cysts in four patients, pancreatic cysts in three patients, and 
an epididymal cystadenoma in one patient. 
 There are two case reports in the literature of epididymal 
cysts forming the first clinical manifestation of VHL [13, 
14], one of which occurred in association with early-onset 
renal cell carcinoma. Epididymal cystadenomas have no 
established genotypic association [15], and we had only one 
patient with this manifestation in our cohort. Renal cysts are 
usually asymptomatic and found on screening in 
approximately 15% of patients with VHL disease [4, 16]. 
They are considered precursors to malignancy, but 
transformation appears uncommon [15]. In this study group, 
renal cysts were not associated with any specific genotype. 
Pancreatic cysts are also usually asymptomatic and detected 
on systemic screening; their reported prevalence varies from 
15% to 74% of patients with VHL disease, with one recent 
systematic review finding an overall prevalence of 60% [17-
20]. In our study, 3 patients (14%) had pancreatic cysts. All 
of these patients had VHL gene deletions and all developed 
CNS HGB at some stage. This association has been 
previously reported, but only one study contains genotypic 
data [17, 21]. 
 The small numbers of patients included in our study and 
limited follow-up make it impossible to make any definitive 
conclusions about the genotypes and phenotypes of visceral 
Table 1. Disease Manifestations at Presentation and During Follow-Up for Patients with Cystic Visceral Lesions 
 
Lesions at Presentation New Lesions During Follow-Up 
ID Mutation 
Cystic  
Visceral  
Other  
Visceral  
CNS  Ocular  
Cystic  
Visceral 
Other  
Visceral 
CNS Ocular 
1 MissenseExon 1 
Epididymal  
cystadenoma 
   
Renal  
cyst 
  
2 x Right  
peripheral RCH 
2 
Missense  
(variant) 
Renal cyst     
Bilateral  
PCC 
  
3 Deletion Exons 1 - 3   
Spinal cord  
HGB 
 
Pancreatic  
cyst 
 
Cerebellar  
HGB 
 
4 Deletion Exon 3   
Spinal cord  
HGB 
 
Renal  
cyst 
 
Cerebellar  
HGB 
 
5 Deletion Exons 1-3   
Cerebellar  
HGB 
 
Pancreatic  
cyst 
Renal cyst 
    
6 Deletion Exon 2    
Right peripheral  
RCH 
Pancreatic  
cyst 
 Spinal cord HGB  
HGB, haemangioblastoma; PCC, phaeochromocytoma; RCH, retinal capillary haemangioma. 
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cystic lesions. Nevertheless, our study does provide some 
supporting evidence for the previously observed phenotype 
comprising pancreatic cysts and CNS HGB linked to VHL 
deletions. In addition, one of our principal aims in 
performing this study was to see whether there was any 
association between visceral cystic lesions and ocular 
involvement. Although our small numbers again require us 
to be guarded in our conclusions, our failure to find any 
association suggests that further ocular study of a larger 
population of patients with visceral cystic lesions would be 
unlikely to prove rewarding. 
 In conclusion, we present the findings of clinical and 
molecular examination of a small group of patients with 
visceral cystic lesions in VHL disease. Pancreatic cysts 
appeared to be associated with VHL deletions, but ocular 
involvement was uncommon in this group of patients. 
SUMMARY 
 This paper describes the phenotype of a cohort of patients 
with von Hippel-Lindau disease who developed visceral 
cystic lesions. Genotyping results suggested that VHL gene 
deletions may be associated with pancreatic cysts and the 
development of central nervous system haemangioblastomas. 
Ocular manifestations proved uncommon in this group of 
patients. 
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